Research programme: human monoclonal antibody therapeutics - diaDexus/Medarex

Drug Profile

Research programme: human monoclonal antibody therapeutics - diaDexus/Medarex

Alternative Names: Human monoclonal antibody therapeutics research programme - diaDexus/Medarex

Latest Information Update: 30 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator diaDexus; Medarex
  • Developer diaDexus Inc; Medarex
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Lung cancer; Ovarian cancer

Most Recent Events

  • 28 Jul 2010 diaDexus has been acquired by VaxGen
  • 31 May 2010 Discontinued - Preclinical for Cancer in USA (Parenteral)
  • 31 May 2010 Discontinued - Preclinical for Ovarian cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top